ESMO 2019: Combination immunotherapy drugs offer new hope for melanoma patients 28 Sep 2019 A combination of two immunotherapy drugs, ipilimumab and nivolumab, stops or reverses the progression of advanced melanoma – with long term survival rates hitting an all-time high – according to a study presented at the ESMO Congress. Find out more Show/Hide